Evaluating the De-Escalation of Surveillance for Patients Who Have Undergone Curative Treatment for Breast Cancer

Summary

Patients who were diagnosed with breast cancer and have finished their treatment will be given the opportunity to be part of this study. These patients will have been attending surveillance at the Breast Centre in Beaumont Hospital, Ireland for 2 years prior. These patients, who are doing well after breast cancer treatment, will be given the opportunity to enrol in this study, potentially being discharged from in person surveillance after 2 years, while still attending for their annual mammogram. Investigators intend to find out if a simpler follow-up plan could work just as safely, while also improving the patients quality of life.

Eligibility

Inclusion Criteria:

* Female participants aged 18 years or older
* Prior diagnosis of primary breast cancer treated with curative intent
* Currently under cancer surveillance and at the 24-month follow-up timepoint
* No clinical or radiological evidence of disease recurrence or metastasis at the time of recruitment (e.g., no palpable mass, skin or nipple changes, or suspicious findings on imaging)
* Able to read, write, and speak English sufficiently to complete the EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire (paper-based or via telephone)
* Resident in the Republic of Ireland with a fixed address and intention to continue follow-up within the Irish healthcare system

Exclusion Criteria:

* Evidence of breast cancer recurrence or metastatic disease at the time of recruitment
* Inability to provide informed consent
* Inability to complete study questionnaires (e.g., due to language barriers or cognitive impairment)
* Not resident in the Republic of Ireland or not intending to remain in follow-up within the Irish healthcare system

Conditions2

Browse More Trials